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SUMMARY. The aim of the work is to study the main 
characteristics of HIV-associated diseases of the central 
nervous system in persons over 50 years old and to 
determine the frequency and relationship of chances of 
development of neurological diseases depending on age 
aspects.
Patients and methods. A retrospective analysis of 428 
medical cards of patients with HIV-associated CNS diseases 
who were treated at the departments of Dnipropetrovsk 
regional and municipal AIDS centers in the period from 2010 
to 2016 was conducted. Central nervous system diseases 
included cerebral tuberculosis, toxoplasmosis, fungal 
infections, neoplasms, encephalitis caused by Epstein-Barr 
virus, progressive multifocal leukoencephalopathy; cognitive 
impairments were analysed separately. The main study 
group included 51 patients (11.9 %) over the age of 50 
years, the comparison group consisted of persons younger 
than 50 years old – 377 patients (88.1 %). Statistical 
processing of the results of the study was conducted using 
the programs STATISTICA v.6.1® and SPSS v.13. Levels 
of CD4 cell count and RNA HIV viral load were taken into 
account during the development of neurological diseases.
Results. In the group of patients over 50, a tendency 
to a higher mortality rate was determined – 52.9 % vs. 
43.0 % in the younger group (p=0.229 FET). In majority of 
the patients in the main group (52.9 %) HIV infection was 
diagnosed during visits due to neurological symptoms. The 
average time from the detection of HIV to the development 
of neurological symptoms was lower than in the comparison 
group, respectively 0.0 (IQR 0.0-2.5) years and 1.0 (IQR 
0.0-6.0) years (p=0.012 W). The majority of patients in the 
main group had sexual route of transmission (61.8 %), 
whereas in the comparator group, the majority of patients 
(62.0 %) were infected during intravenous drug usage 
(p=0.009 FET). Antiretroviral therapy in the main group was 
received by significantly fewer patients – 23.5 % vs. 40.3 % 
in the comparison group (p=0.022 FET). The patients in the 
main group did not show statistical differences with the 
comparison group regarding CD4 cell count level – 
respectively 48.5 (IQR 15.25-206) cells/μL and 65.0 (IQR 
20.75-175.25) cells/μL (p=0.601 U), while the median VL 
of the HIV RNA was 1.2 times higher in this group – 5.72 
(IQR 4.74-5.89) copies/ml versus 4.9 (IQR 2.03-5.61) 
copies/ml (p=0.047 U).
In the structure of CNS diseases in both groups, 
tuberculosis of the central nervous system predominated. 
The age correlations with HIV-associated cognitive 
impairment, progressive multifocal leukoencephalopathy 
and the risk of developing of cerebrovascular disease 
(Stroke) have been identified. The chances of development 
of cognitive disturbances in patients over the age of 50 
were 4.26 (95 % CI 2.29-7.93) times higher than in 
younger HIV-infected patients. It was also found that in 
this group, cognitive disturbanceswith the background of 
ART were more frequently diagnosed than in the 
comparison group (58.3 versus 25.0 %, p=0.020 FET). 
Patients older than 50 years of age were also more likely 
to be diagnosed with EBV-encephalitis (p=0.052 FET), 
the probability of development of which in this group was 
2.24 (95 % CI 1.04-4.84) times higher than in the 
comparison group.
Conclusions. The obtained data testify to the features 
of HIV-associated diseases of the CNS in patients over the 
age of 50 years. In this age group, the number of people 
infected with sexualroute of transmission was significantly 
higher than among younger people, the HIV infection was 
diagnosed later and, accordingly, fewer patients received 
ART. At the time of the development of neurological 
diseases in patients over 50, a higher level of RNA HIV viral 
load was observed in the absence of statistically significant 
immunological differences. In this group, high chances of 





and a tendency towards higher incidence of stroke are 
identified, which can lead to severe consequences, and 
underlines the importance of a more detailed consideration 
of the age aspect.
Key words: HIV-infection, HIV-associated diseases of 
the central nervous system, age, cognitive impairment.
Aging of the population is now becoming a global 
medical and social problem in many countries of the world. 
It is estimated that the number of HIV-positive people over 
the age of 50 in developed countries is over 10 %. It is 
expected that this percentage will continue to increase due 
to the improvement in the life expectancy of patients 
assigned to highly active antiretroviral therapy (HAART) [1]. 
Given the growing number of elderly people infected with 
HIV, there is a growing need for a study on the relationship 
between HIV and aging. Thus, it is suggested that active 
antiviral therapy and long life expectancy of patients can 
lead to a number of risks affecting quality of life, and such 
manifestations of aging as psychiatric diseases, 
neurocognitive disorders, metabolic and hormonal 
dysfunctions may depend on the chronic effects of HIV and/
or therapy HIV [2].
It is believed that aging and HIV have a complex effect 
on immune cell dysfunction, which includes decreased 
phagocyte activity, cytolytic function of natural killer cells, 
expression of toll-like receptors and interleukin-12 
production [3]. Elderly people are generally less likely to be 
suggested HIV testing than younger ones, which often leads 
to much later diagnosis of HIV infection in this category. 
Studies conducted by several authors have shown that in 
elderly patients at the time of diagnosis of HIV, the number 
of CD4 + lymphocytes is lower than that of younger people 
[4]. At the same time, data on possible differences in the 
level of viral load at the onset of treatment and the virological 
response to HAART in elderly and younger patients are 
contradictory in various studies [4, 5, 6]. According to the 
literature, decreased level of neurocognitive functioning in 
elderly patients is a major predictor of decreased adherence 
to ART and, accordingly, the risk of ART failures at the age 
of 50 years and older is generally associated with 
neurocognitive status. [7]. Since age can affect the 
progression of HIV infection and the structure of comorbid 
conditions, careful study of the specificities of the 
development of HIV-associated neurological diseases in 
older patients is required for more effective prediction and 
diagnosis, as well as the proper differential diagnosis of 
these diseases with age-related changes in the nervous 
system [8, 9].
Aim – to study the main characteristics of HIV-
associated CNS diseases in persons over 50 years of age 
and to determine the frequency and ratio of odds ratio of 
development of neurological diseases depending on age 
aspects.
Patients and methods
The study encompassed retrospective analysis of 428 
medical records of adult patients with HIV-associated CNS 
diseases that were hospitalized and treated at the departments 
of the Dnipropetrovsk regional and municipal AIDS prevention 
and management centers in the period from 2010 to 2016, with 
appropriate records in medical charts. The study included HIV-
positive patients aged 19 to 67 years with the most common 
diseases of the central nervous system in the Dnipropetrovsk 
region, including cerebral tuberculosis, toxoplasmosis, fungal 
etiology (candidiasis and cryptococcosis were grouped 
together), neoplasms, encephalitis caused by Epstein-Barr 
virus (EBV), progressive multifocal leukoencephalopathy 
(PML), stroke and encephalitis of unspecified etiology. In 
addition, the above mentioned diseases of the central nervous 
system, which were accompanied by cognitive impairments, 
were separately analyzed. The description of cognitive 
impairment was available in medical records. Levels of CD4 
cell count and RNA HIV viral load were taken into account 
during the development of neurological diseases.
The main group of the study included 51 patients (11.9 %), 
over the age of 50 years. The comparison group included 
persons younger than 50 years old – 377 patients (88.1 %).
The statistical processing of the research results was 
carried out using the application packages STATISTICA v.6.1® 
and SPSS v.13. The parametric and nonparametric 
characteristics and comparison methods were used for the 
normal distribution law (Shapiro-Wilk’s W test): for the normal 
distribution law, the arithmetic mean (M), standard error (m), 
Independent-Samples T-Test (T) ; in other cases, the median 
(Me), the interquartile range (IQR), the Mann-Whitney U Test 
(U) criterion. Comparison of relative indices was performed on 
two-tailed Fisher’s Exact Test (FET). In order to compare the 
incidence of HIV-associated CNS diseases and cognitive 
impairment in groups, odds ratios (ORs) with confidence 
intervals (95 % CI) were determined.
Results and discussion
The average age of patients in the main group during 
the development of neurological diseases was (52.96±0.49) 
years, median (Me) – 52 (IQR 50-54) years. In the 
comparison group, these figures were – (36.7±0.30) years, 
Me – 37.0 (IQR 33-41) years. As can be seen from Table 1, 
the main group and the comparison group were statistically 
comparable in the sex of patients with prevalence of males 
– 64.7 % and 57.0 %, respectively, in groups (p=0.365 FET), 
and also in the level of CD4 cell count – 48.5 (IQR 15.25-
206) cells/μL and 65.0 (IQR 20.75-175.25) cells/μL 





the main group was noted – 52.9 % vs. 43.0 % in the 
younger age group (p=0.229 FET). Most (52.9 %) of patients 
over 50 years of age were found late in the period of the 
diagnosis of neurological diseases, which corresponded to 
the 4th clinical stage of HIV infection. The mean time from 
the time of HIV detection to the development of neurological 
symptoms in the main group was lower than in the 
comparison group, respectively, 0.0 (IQR 0.0-2.5) years 
and 1.0 (IQR 0.0-6.0 ) years (p=0.012 U) (Table 1).
Table 1
Characteristics of patients with HIV-related CNS diseases older than 50 years and older
Characteristics
The comparison 
group The main group
The significance 
of the differences 
between the group<50 years ≥50 years
Male sex, n (%) 215 (57.0 %) 33 (64.7 %) р=0.365 FET
Fatal cases, n (%) 162 (43.0 %) 27 (52.9 %) р=0.229 FET
HIV transmission pathway, number of 
patients in %
parenteral (IDU) 62.0 % 38.2 %
р=0.009 FET
sexual 38.0 % 61.8 %
TheaveragedurationoftheperiodfromtheestablishmentofHIVst
atustothedevelopmentofneurologicalsymptoms, Me (IQR), 
years
1.0 (0.0–6.0) 0,0 (0.0–2.5) р=0.012 U
CD4 cell count in the development of neurological diseases, 






Lg RNA HIV viral load during the development of neurological 






Patients who received ART, n (%) 152 (40.3 %) 12 (23.5 %) р=0.022 FET
Patients older than 50 years of age (the main group) 
had the prevalence of sexually transmitted infections 
(61.8 % of patients), while in the comparison group, the 
majority of patients (62 %) were infected with intravenous 
drug use (p=0.009 FET). Antiretroviral therapy (ART) 
covered 40.3 % of patients under the age of 50 years and 
only 23.5 % of patients in the main group (p=0.022 FET), 
which correlated with a short period of follow-up. At the 
same time, the median lg RNA of HIV viral load in them was 
1.2 times higher than in younger patients – 5.72 (IQR 4.74-
5.89) copies/ml versus 4.9 (IQR 2.03-5.61) copies/ml at 
p=0.047 U.
In the structure of CNS diseases (Table 2), in patients 
of the main group, as well as among young people, CNS 
tuberculosis dominated.
Table 2
Frequency and proportion of chances of development of HIV-associated neurological diseases  
in patients older than 50 years old
CNS Diseases




<50 years ≥50 years
% % OR (95 % CI)
Tuberculosis 40.8 39.2 0.93 (0.51–1.70) 0.880
Fungal infection (yeast fungi) 16.7 15.7 0.93 (0.42–2.07) 1.00
EBV-encephalitis 9.8 19.6 2.24 (1.04–4.84) 0.052
Progressive multifocal 
leukoencephalopathy (PML)
4.8 13.7 3.17 (1.26–8.02) 0.020
Toxoplasmosis 26.8 21.6 0.75 (0.37–1.52) 0.499
Stroke 1.6 3.9 2,52 (0.50–12.80) 0.245
Encephalitis unspecified 13.0 5.9 0.42 (0.13–1.40) 0.174
Brain tumors 1.1 0 0.99 (0.98–1,00) 1.00





Age associations with HIV-1-associated cognitive 
impairment, progressive multifocal leukoencephalopathy 
and the risk of developing cerebrovascular pathology 
(stroke) have been determined, which coincides with the 
literature [10]. As can be seen from Table 2, the chances of 
development of cognitive impairment in patients over the 
age of 50 were 4.26 (95 % CI 2.29-7.93) times higher than 
those of younger HIV-infected patients. It was found that in 
individuals in this group, cognitive impairment on the 
background of ART was more frequent than in the 
comparison group (58.3 versus 25.0 %, p=0.020 FET). The 
reasons could include some changes associated with aging, 
such as: selective destruction of neurons in the hippocampus 
[11], formation of amyloid plaques [12]; the toxic effect of 
drugs [2], as well as the limited penetration of some 
antiretroviral drugs through the blood-brain barrier [11, 13], 
which requires a detailed analysis of the composition of 
ART regimens and the determination of HIV viral load in 
the CSF. In the group over 50 years of age, PML was also 
more often diagnosed (p=0.020 FET). The risk of developing 
this disease in this group was 3.17 (95 % CI 1.26-8.02) 
times higher than that of younger people and may have 
been due to a higher viral load. Older patients also showed 
tendency to a higher incidence of stroke, which may be 
more closely related to age with an increase in the number 
of observations and greater age separation. Patients older 
than 50 years of age were more likely to be diagnosed with 
EBV-encephalitis (p=0.052 FET), the chances of which in 
this group were 2.24 (95 % CI 1.04–4.84) times higher than 
in the comparison group, which may be due to the fact that 
the aging immune system, even in people without HIV, is 
characterized by clonal expansion of CD8 + T cells and 
cannot control the reactivation of EBV and CMV [14]. It is 
also considered that the effect of age on the EBV-specific 
response depends on the serological status of CMV, so, in 
the seronegative to CMV patients, the response of CD8 to 
EBV cells significantly increases with age and results in the 
suppression of virus-specific immunity during aging [15]. 
These factors require further in-depth study of patients of 
older age with HIV infection and EBV infection.
Conclusions
The obtained data testify to the peculiarities of HIV-
associated CNS diseases in patients over 50 years of age. 
In this age category, the number of people infected by sexual 
route was significantly higher than among younger people. 
Persons older than 50 years were diagnosed with HIV later 
than younger ones and, accordingly, there was a lower 
coverage of ART. At the time of the development of 
neurological diseases, higher HIV RNA viral load was 
observed in the absence of statistically significant 
immunological differences. Patients over 50 have high 
chances of developing PML, EBV-encephalitis, cognitive 
impairment, and a tendency to higher incidence of stroke, 
which can lead to severe consequences and emphasizes 
the importance of more detailed consideration of age-related 
aspects, as well as rationalization of management in this 
group to improve the quality of life of patients.
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ХАРАКТЕРИСТИКА ВІЛ-АСОЦІЙОВАНИХ 
ЗАХВОРЮВАНЬ ЦЕНТРАЛЬНОЇ 
НЕРВОВОЇ СИСТЕМИ В ОСІБ СТАРШОГО 
ВІКУ
Л.Р. Шостакович-Корецька1, К.Ю. Литвин1, І.О. Губар1, 
З.О. Чикаренко1, О.О. Волікова1, І.В. Чухалова2, О.О. Лiснича3
1ДЗ «Дніпропетровська медична академія МОЗ України», 
2КЗ «Дніпропетровський обласний центр з профілактики 
та боротьби зі СНІДом»,
3КЗ «Дніпропетровська міська клінічна лікарня № 21 
ім. Є.Г. Попкової» ДОР», Дніпропетровський міський центр з 
профілактики та боротьби зі СНІДом
РЕЗЮМЕ. Мета роботи – вивчити основні харак-
теристики ВІЛ-асоційованих захворювань цен-
тральної нервової системи в осіб старше 50 років 
і визначити частоту і відношення шансів розвитку 
неврологічних захворювань залежно від вікових ас-
пектів.
Пацієнти і методи. Проведений ретроспективний 
аналіз 428 медичних карт пацієнтів з ВІЛ-асоці-
йованими захворюваннями ЦНС, які перебували на 
лікуванні у відділеннях Дніпропетровського облас-
ного та міського центрів СНІД в період з 2010 по 





ний туберкульоз, токсоплазмоз, ураження грибко-
вої етіології, новоутворення, енцефаліти, які ви-
кликані Епштейна-Барр вірусом, прогресуючу 
мультифокальну лейкоенцефалопатію та окремо 
аналізувалися когнітивні порушення. До основної 
групи дослідження був включений 51 пацієнт 
(11,9 %), віком старше 50 років, групу порівняння 
склали особи молодші 50 років – 377 пацієнтів 
(88,1 %). Статистична обробка результатів до-
слідження проводилася з використанням програм 
STATISTICA v.6.1® и SPSS v.13. Показники CD4 
cellcount и RNA HIV viralload враховувались у період 
розвитку неврологічних захворювань.
Результати. У групі пацієнтів старше 50 років 
визначена тенденція до більшої летальності – 52,9 
проти 43,0 % у групі молодших осіб (р=0,229 FET). 
У більшості (52,9 %) пацієнтів основної групи ВІЛ-
інфекцію було діагностовано при зверненні з при-
воду неврологічних симптомів. Середній час від 
виявлення ВІЛ до розвитку неврологічних симпто-
мів був нижчим, ніж у групі порівняння, відповідно 
0,0 (IQR 0,0-2,5) і 1,0 (IQR 0,0-6,0) років (р=0,012 W). 
У пацієнтів основної групи переважав статевий 
шлях інфікування ВІЛ (61,8 %), а в групі порівняння 
– більшість пацієнтів (62 %) була інфікована при 
внутрішньовенному вживанні наркотиків (р=0,009 
FET). Антиретровірусну терапію в основній групі 
отримувало значно менше пацієнтів – 23,5 проти 
40,3 % у групі порівняння (р=0,022 FET). У пацієнтів 
основної групи не виявлено статистичних відмін-
ностей з групою порівняння в рівні CD4 cellcount – 
відповідно – 48,5 (IQR 15,25-206) cells/μL та 65,0 
(IQR 20,75-175,25) cells/μL (р=0,601 U) при тому, що 
медіана ВН РНК ВІЛ у них була в 1,2 разу вище – 5,72 
(IQR 4,74-5,89) копій/мл проти 4,9 (IQR 2,03-5,61) 
копій/мл (р=0,047 U). 
У структурі захворювань ЦНС в обох групах пере-
важав туберкульоз ЦНС. Визначені вікові асоціації 
з ВІЛ-асоційованими когнітивними порушеннями, 
прогресуючою мультифокальною лейкоенцефало-
патією та ризиком розвитку цереброваскулярної 
патології (Stroke). Шанси розвитку когнітивних 
порушень у пацієнтів старше 50 років були в 4,26 
(95 % СІ 2,29-7,93) разу вище, ніж у молодших ВІЛ-
інфікованих пацієнтів. При цьому встановлено, що 
в осіб цієї групи когнітивні порушення на фоні при-
йому АРТ розвивалися частіше, ніж у пацієнтів 
групи порівняння (58,3 проти 25,0 %, р=0,020 FET). 
У пацієнтів старше 50 років також частіше діаг-
ностували ЕБВ-енцефаліти (р=0,052 FET), шанси 
розвитку яких у даній групі були в 2,24 (95 % СI 
1,04-4,84) разу вище, ніж у групі порівняння.
Висновки. Отримані дані свідчать про особливос-
ті ВІЛ-асоційованих захворювань ЦНС у пацієнтів 
старше 50 років. У даній віковій категорії число осіб, 
інфікованих статевим шляхом, було значно більше, 
ніж серед молодших осіб, ВІЛ-інфекцію було діаг-
ностовано пізніше і, відповідно, менша кількість 
пацієнтів отримувала АРТ. На момент розвитку 
неврологічних захворювань у пацієнтів старше 
50 років спостерігався більший рівень RNA HIV 
viralload при відсутності статистично значущих 
імунологічних відмінностей. В даній групі визначені 
високі шанси розвитку ПМЛ, EBV-енцефалітів, 
когнітивних розладів і тенденцію до більшої часто-
ти інсультів, що може призводити до тяжких на-
слідків, і підкреслює важливість більш детального 
обліку вікового аспекту.
Ключові слова: ВІЛ-інфекція, ВІЛ-асоційовані за-
хворювання ЦНС, вік, когнітивні порушення.
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